06.03.2025 • News

ADNOC and OMV to Create Global Polyolefins Group

OMV and ADNOC agreed to combine their Borealis and Borouge shareholdings into Borouge Group International. ADNOC has also signed a share purchase agreement with Nova Chemicals, an indirect wholly owned subsidiary of Mubadala Investment Company, to acquire 100% of Nova Chemicals for an enterprise value of $13.4 billion. In addition, ADNOC and OMV have agreed for Borouge Group International to take over Nova Chemicals after closing.

Once fully operational, Borouge 4 is envisaged to be retransferred to Borouge Group International at the end of 2026 at an estimated cost of around $7.5 billion. When combined, the three highly complementary businesses will create the fourth-largest global polyolefin group with equal shareholdings by OMV and ADNOC, the companies said.

The acquisition of Nova Chemicals, a North American-based polyolefin producer, will further strengthen Borouge Group International’s presence across the Americas and increase its exposure to advantaged feedstock.

Alfred Stern, CEO of OMV, said: “These landmark transactions represent a momentous step for OMV. They will accelerate our growth strategy in Chemicals and support OMV’s transformation into an integrated sustainable chemicals, fuels, and energy company.”

Ahmed Al Jaber, ADNOC’s group CEO, added: “The visionary combination of Borouge and Borealis and acquisition of Nova Chemicals, further future-proofs ADNOC and solidifies Abu Dhabi's status as a leader in the chemicals sector, as we seek to meet the growing global demand for chemicals and associated products, while driving value creation and growth opportunities for our shareholders."

Under the terms of the transactions, Borealis and Borouge will be combined, and OMV will inject €1.6 billion in cash into Borouge Group International to equalize shareholdings.

The new entity will be headquartered in Vienna, Austria, with regional headquarters in Abu Dhabi.

© RonFullHD/Getty Images
© RonFullHD/Getty Images

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

most read